These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35738428)

  • 21. Machine learning approaches in predicting allosteric sites.
    Nerín-Fonz F; Cournia Z
    Curr Opin Struct Biol; 2024 Apr; 85():102774. PubMed ID: 38354652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots).
    MacKerell AD; Jo S; Lakkaraju SK; Lind C; Yu W
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129519. PubMed ID: 31911242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of receptor allosterism.
    Gregory KJ; Sexton PM; Christopoulos A
    Curr Protoc Pharmacol; 2010 Dec; Chapter 1():Unit 1.21. PubMed ID: 21935895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of allosteric targets in the discovery of safer drugs.
    Grover AK
    Med Princ Pract; 2013; 22(5):418-26. PubMed ID: 23711993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms.
    Lu S; Shen Q; Zhang J
    Acc Chem Res; 2019 Feb; 52(2):492-500. PubMed ID: 30688063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational elucidation of allosteric communication in proteins for allosteric drug design.
    Ni D; Liu Y; Kong R; Yu Z; Lu S; Zhang J
    Drug Discov Today; 2022 Aug; 27(8):2226-2234. PubMed ID: 35314339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-talk between allosteric and orthosteric binding sites of γ-amino butyric acid type A receptors (GABA
    Payghan PV; Nath Roy S; Bhattacharyya D; Ghoshal N
    J Biomol Struct Dyn; 2019 Aug; 37(12):3065-3080. PubMed ID: 30608219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motions of Allosteric and Orthosteric Ligand-Binding Sites in Proteins are Highly Correlated.
    Ma X; Meng H; Lai L
    J Chem Inf Model; 2016 Sep; 56(9):1725-33. PubMed ID: 27580047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The different ways through which specificity works in orthosteric and allosteric drugs.
    Nussinov R; Tsai CJ
    Curr Pharm Des; 2012; 18(9):1311-6. PubMed ID: 22316155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of Protein Allosteric Signalling Pathways and Functional Residues Through Paths of Optimised Propensity.
    Wu N; Yaliraki SN; Barahona M
    J Mol Biol; 2022 Sep; 434(17):167749. PubMed ID: 35841931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations.
    Mingione VR; Foda ZH; Paung Y; Philipose H; Rangwala AM; Shan Y; Seeliger MA
    J Mol Biol; 2022 Sep; 434(17):167628. PubMed ID: 35595169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs.
    Hudson BD; Ulven T; Milligan G
    Curr Top Med Chem; 2013; 13(1):14-25. PubMed ID: 23409763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conservation and Diversity in Allosteric Fingerprints of Proteins for Evolutionary-inspired Engineering and Design.
    Tee WV; Tan ZW; Guarnera E; Berezovsky IN
    J Mol Biol; 2022 Sep; 434(17):167577. PubMed ID: 35395233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allosteric Modulators of the Class A G Protein Coupled Receptors.
    Tschammer N
    Adv Exp Med Biol; 2016; 917():185-207. PubMed ID: 27236557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AlloSigMA 2: paving the way to designing allosteric effectors and to exploring allosteric effects of mutations.
    Tan ZW; Guarnera E; Tee WV; Berezovsky IN
    Nucleic Acids Res; 2020 Jul; 48(W1):W116-W124. PubMed ID: 32392302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ASBench: benchmarking sets for allosteric discovery.
    Huang W; Wang G; Shen Q; Liu X; Lu S; Geng L; Huang Z; Zhang J
    Bioinformatics; 2015 Aug; 31(15):2598-600. PubMed ID: 25810427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and Future Challenges in GPCR Drug Discovery.
    Topiol S
    Methods Mol Biol; 2018; 1705():1-21. PubMed ID: 29188556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hidden allosteric sites and De-Novo drug design.
    Rehman AU; Lu S; Khan AA; Khurshid B; Rasheed S; Wadood A; Zhang J
    Expert Opin Drug Discov; 2022 Mar; 17(3):283-295. PubMed ID: 34933653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.
    Janero DR; Thakur GA
    Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.
    Lu S; He X; Ni D; Zhang J
    J Med Chem; 2019 Jul; 62(14):6405-6421. PubMed ID: 30817889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.